Home » News » Ethics/Regulatory » NCPA statement on nomination of Alex Azar to be HHS Secretary

NCPA statement on nomination of Alex Azar to be HHS Secretary

Tuesday, November 14, 2017

National Community Pharmacists Association CEO B. Douglas Hoey, Pharmacist, MBA, issued the following statement on President Donald Trump’s nomination of Alex Azar, a former executive at Eli Lilly & Co., to lead the U.S. Department of Health and Human Services:

“We congratulate Alex Azar on his nomination to be the next HHS Secretary. His background in the pharmaceutical industry means he brings an understanding of supply chain issues and players that will be helpful to him in this role.

“We look forward to sharing independent community pharmacists’ insights about how to make the system more transparent, increase patient access to prescription drugs, and reduce health care spending and drive better health outcomes in the process.

“NCPA and the 22,000 independent community pharmacies it represents will continue to push for common-sense, market-based, bipartisan reforms in the delivery of critical prescription medications and health care services to Americans.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!